Omvoh is the first biologic treatment in more than 15 years to have disclosed two-year Phase 3 efficacy data in Crohn's disease at the time of approval. 2 "The burden of Crohn's disease on patients' ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Marquis Who's Who honors Jan M. Lundberg, PhD, for his expertise in pharmaceuticals and research. Dr. Lundberg has over 30 years of professional experience in the pharmaceutical industry.

Eli Lilly's stock dipped due to cutting Q4 sales targets, despite a strong 2024 performance from Mounjaro and Zepbound. Click ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 465.16% and ...

Eli Lilly (LLY) reduced its fourth-quarter sales guidance by 5%, lowering expectations to $13.5 billion. This figure is $400 ...

Joe Biden Announces Stimulus Checks for People Impacted by California Fires 14 Rare Animals That Look Too Bizarre to Be Real Meta targeting lowest-performing employees in latest round of layoffs I've ...

The FDA approved Eli Lilly’s Omvoh in Crohn’s disease, the company announced Wednesday, handing the drug its second ...

Eli Lilly expects to miss its recent revenue estimate for 2024 by about $400 million, according to a preliminary report.

Undervalued biotech company Regenxbio Inc. shows promise with cutting-edge gene therapy technology for AMD and MPS II. Click ...

Prediction market platform Kalshi has announced Donald Trump Jr. as its new strategic adviser. Kalshi CEO Tarek Mansour joins ...

Asian stocks were mixed Wednesday followed Wall Street’s mostly positive performance ahead of key U.S. inflation data that ...